Effect of continuous infusion of esmolol or magnesium sulfate during laparoscopic cholecystectomy on postoperative recovery quality

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100041755

Enrollment

Unknown

Registered

2021-01-04

Start date

2021-01-15

Completion date

Unknown

Last updated

2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystitis

Interventions

Group E:Esmolol

Group M:Magnesium

Group C:Saline

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing laparoscopic cholecystectomy under general anesthesia; 2. Patients aged 20-65 years; 3. ASA I - II; 4. Subjects with BMI of 18-28kg / m2.

Exclusion criteria

Exclusion criteria: 1. Patients who have experienced pain before operation for any reason and patients who take analgesic drugs; 2. Pregnant or lactating patients; 3. Patients with severe heart, liver or kidney diseases; 4. Patients with mental or neurological diseases; 5. Patients with contraindications or hypersensitivity to esmolol or magnesium sulfate.

Design outcomes

Primary

Measure	Time frame
QoR-15 score;	—

Secondary

Measure	Time frame
Dosage of propofol;Dosage of remifentanil;Heart rate;Blood pressure;VAS score;Nausea and vomiting;	—

Countries

China

Contacts

Public ContactAnshi Wu

Beijing Chaoyang Hospital Affiliated to Capital Medical University

wuanshi@hotmail.com+86 13511010883

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026